Navigation Links
Drug Cures Osteoporosis in Mice
Date:2/8/2010

Experimental agent targets serotonin in the gut, triggering bone formation

MONDAY, Feb. 8 (HealthDay News) -- An experimental drug that inhibits serotonin in the gut cured osteoporosis in lab mice and rats, a new study has found.

Previous research has shown that serotonin in the gut hinders bone formation. Most current drugs for osteoporosis only prevent the breakdown of bone; they don't build bone.

"New therapies that inhibit the production of serotonin in the gut have the potential to become a [new] class of drugs to be added to the therapeutic arsenal against osteoporosis," study author Dr. Gerard Karsenty, chairman of the department of genetics and development at Columbia University College of Physicians and Surgeons, said in a university news release.

In the new study, published in the Feb. 7 issue of Nature Medicine, small daily doses of the new drug were given by mouth for up to six weeks to rodents with postmenopausal osteoporosis. The treatment prevented osteoporosis from developing or fully cured rodents in which osteoporosis was already present.

While the drug inhibited serotonin in the gut, levels of serotonin remained normal in the rodents' brains. This indicates that the drug didn't enter general circulation and wasn't able to cross the blood-brain barrier, thus greatly reducing the risk of side effects.

"With tens of millions of people worldwide affected by this devastating and debilitating bone loss, there is an urgent need for new treatments that not only stop bone loss but also build new bone. Using these findings, we are working hard to develop this type of treatment for human patients," Karsenty said.

More information

The American College of Rheumatology has more about osteoporosis.



-- Robert Preidt



SOURCE: Columbia University, news release, Feb. 7, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Constipations Many Causes and Cures
2. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
3. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
4. Revised California Stem Cell Research Rules Fail to Ensure Affordable Access to Cures, Consumers Warn
5. UI licensee Optherion secures $37 million in financing
6. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
7. Piedmont Pharmaceuticals Secures $8.5 Million Investment
8. St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chilis Care Center
9. The blood-brain barrier: A misunderstood key to finding life-saving cures to brain disease
10. Study paves way for development of macular degeneration cures
11. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: